Seer Partners with Singapore on 10,000-Sample Proteomics Study — Seer, Inc.

Event summary

Seer’s Proteograph® Product Suite selected for deep, unbiased proteomics on 10,000 samples from Singapore’s PRECISE-SG100K cohort.
Study integrates Seer’s mass spectrometry-based proteomics with Thermo Fisher’s Olink® Reveal and Orbitrap Astral™ mass spectrometers.
PRECISE-SG100K aims to be one of the world’s most comprehensive multi-omic datasets, focusing on Asian populations.
Data expected to support biomarker discovery, drug target biology, and predictive models for disease risk.

The big picture

This collaboration underscores the growing importance of deep, unbiased proteomics in large-scale population studies. By integrating proteomic data with genomic and phenotypic information, the study aims to advance precision health and therapeutic discovery, particularly in underrepresented Asian populations. The partnership also highlights the increasing demand for high-throughput, mass spectrometry-based proteomics in multi-omic research.

What we're watching

Data Integration: How Seer’s Proteograph platform will complement Thermo Fisher’s tools to enhance proteomic insights.
Market Expansion: Whether this collaboration will position Seer as a key player in large-scale proteomic studies.
Biomarker Validation: The pace at which the study will validate biomarkers and uncover insights critical to precision medicine.